Filling in the gaps in PARP inhibitor-induced synthetic lethality

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• Tumors lacking breast cancer type 1 susceptibility protein (BRCA1) are homologous recombination (HR) deficient.
• These HR-deficient tumors are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPi).
• Acquired resistance to PARPi can occur through restoration of HR, often involving loss of DNA double-strand break end-protection.

Purpose of the Study:

• To investigate mechanisms of PARPi resistance in BRCA1-deficient tumors.
• To identify therapeutic strategies to overcome PARPi resistance.
• To explore the role of DNA ligase III in HR restoration and PARPi response.

Main Methods:

• Utilized cell models of BRCA1-deficient and HR-restored tumors.
• Assessed the impact of nuclear DNA ligase III depletion on PARPi sensitivity.
• Analyzed the presence of post-replicative single-stranded DNA (ssDNA) gaps.

Main Results:

• Loss of nuclear DNA ligase III resensitized HR-restored BRCA1-deficient cells to PARPi.
• Depletion of DNA ligase III led to the exposure of post-replicative ssDNA gaps.
• ssDNA gaps were identified as a critical factor influencing PARPi response.

Conclusions:

• Nuclear DNA ligase III plays a role in maintaining genome stability in HR-restored cells.
• Targeting DNA ligase III can re-sensitize resistant tumors to PARPi.
• Exposed ssDNA gaps are a key determinant of response to PARPi therapy.